Application of the apparent diffusion coefficient in magnetic resonance imaging in an assessment of the early response to treatment in Hodgkin’s and non-Hodgkin’s lymphoma – pilot study

Patyk, Mateusz; Kwiatkowski, J; Pawluś, Aleksander; Hołownia, Daniel; Szymańska, Kinga; Mazur, Rafał; Silicki, Jurand; Badowski, R; Sokołowska-Dąbek, Dąbrówka; Kuliszkiewicz‐Janus, Małgorzata; Zaleska-Dorobisz, Urszula

doi:10.5114/pjr.2018.76007

Cited by 3 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two former studies have focused on the role of ADC in predicting outcome in systemic lymphoma, but the results are discordant. In line with our results, a study of 39 patients with HL found that disease sites with an inadequate treatment response had significantly higher pretreatment ADC [ 15 ], while a pilot study including 27 patients with HL and NHL found that patients with ADC > 752 mm 2 /s before treatment had a lower probability of progression [ 25 ]. The reason for this discrepancy is hard to postulate.…”

Section: Discussionsupporting

confidence: 87%

Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma

et al. 2022

View full text Add to dashboard Cite

Purpose The aim of this prospective study was to investigate the prognostic value of metabolic tumor volume (MTV) and apparent diffusion coefficient (ADC) from baseline FDG PET/MRI compared to established clinical risk factors in terms of progression free survival (PFS) at 2 years in a cohort of diffuse large B-cell Lymphoma (DLBCL) and high-grade-B-cell lymphoma (HGBCL). Methods Thirty-three patients and their baseline PET/MRI examinations were included. Images were read by two pairs of nuclear medicine physicians and radiologists for defining lymphoma lesions. MTV was computed on PET, and up to six lymphoma target lesions with restricted diffusion was defined for each PET/MRI examination. Minimum ADC (ADCmin) and the corresponding mean ADC (ADCmean) from the target lesion with the lowest ADCmin were included in the analyses. For the combined PET/MRI parameters, the ratio between MTV and the target lesion with the lowest ADCmin (MTV/ADCmin) and the corresponding ADCmean (MTV/ADCmean) was calculated for each patient. Clinical, histological, and PET/MRI parameters were compared between the treatment failure and treatment response group, while survival analyses for each variable was performed by using univariate Cox regression. In case of significant variables in the Cox regression analyses, Kaplan-Meier survival analyses with log-rank test was used to study the effect of the variables on PFS. Results ECOC PS scale ≥2 (p = 0.05) and ADCmean (p = 0.05) were significantly different between the treatment failure group (n = 6) and those with treatment response (n = 27). Survival analyses showed that ADCmean was associated with PFS (p = 0.02, [HR 2.3 for 1 SD increase]), while combining MTV and ADC did not predict outcome. In addition, ECOG PS ≥2 (p = 0.01, [HR 13.3]) and histology of HGBCL (p = 0.02 [HR 7.6]) was significantly associated with PFS. Conclusions ADCmean derived from baseline MRI could be a prognostic imaging biomarker for DLBCL and HGBCL. Baseline staging with PET/MRI could therefore give supplementary prognostic information compared to today’s standard PET/CT.

show abstract

Section: Discussionsupporting

confidence: 87%

Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Among the 15 PET/CT-positive patients (DS 4-5), 3 of them (n. 14,19,21) were also considered MRI-positive (PET+/MRI+ and all 3 had high SUV max values (8; 17.4; 25) and low ADC values (0.9; 1.2; 0.8) with a median value of 0.90 mm 2 /s (Fig. 3): due to the high radiological suspicion of residual disease these 3 patients underwent to mediastinal biopsy for histological confirmation.…”

Section: Resultsmentioning

confidence: 99%

“…To improve post-treatment response assessment, other instrumental investigations, such as diffusion weighted magnetic resonance imaging (DW-MRI), may be added. Actually, DW-MRI is a promising radiation-free technique for staging and following-up many types of neoplasms including lymphomas [20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Comparison between diffusion-weighted magnetic resonance and positron-emission tomography in the evaluation of treated lymphomas with mediastinal involvement

Giuliano

Picchi

Pucci

et al. 2022

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background The persistence of residual tissue after treatment is frequent in patients with mediastinal lymphomas and it is often characterized by 18F-Flurodeoxyglucose Positron Emission Tomography (18F-FDG PET) uptake. This study aims to investigate the usefulness of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) sequence in residual tissues of treated mediastinal lymphomas and to compare it with 18F-FDG PET-CT. Results We included 21 patients with mediastinal Hodgkin and non-Hodgkin lymphomas who showed residual masses on PET-CT imaging at end of treatment and underwent DWIBS-Magnetic Resonance Imaging (MRI). SUVmax and Apparent Diffusion Coefficient (ADC) values of residual masses were assessed quantitatively, including measurement of mean ADC. 15 patients showed radiotracer uptake at 18F-FDG PET-CT, among them only 3 had positive DWIBS-MRI with low ADC values (median value: 0.90 mm2/s). The mediastinal biopsy in these 3 “double positive” patients confirmed pathological residual tissue. All the patients with positive 18F-FDG PET-CT but negative DWIBS-MRI (n = 18) with high ADC values (median value: 2.05 mm2/s) were confirmed negative by biopsy. Conclusions DWIBS-MRI examination combined with ADC measurement allowed to discriminate pathological and non-pathological residual tissue in patients with treated mediastinal lymphoma. These preliminary results seem to pave the way for a leading role of the MRI which could be a useful alternative to the 18F-FDG PET/CT.

show abstract

“…[11]. Die diffusionsgewichtete Bildgebung zeigt vielversprechende Ergebnisse zur Abschätzung eines Therapieansprechens [33].…”

Section: Schilddrüseunclassified

Bildgebung bei Mediastinaltumoren

Ley

Ley‐Zaporozhan

2020

Zentralbl Chir

View full text Add to dashboard Cite

ZusammenfassungDie Einteilung des Mediastinums erfolgt anhand computertomografischer Aufnahmen in ein ventrales prävaskuläres, mittleres viszerales und dorsales paravertebrales Kompartiment. In den einzelnen Kompartimenten kommen verschiedene Tumorentitäten besonders häufig vor, die entsprechend kurz vorgestellt werden. Im Folgenden werden die typischen bildmorphologischen Zeichen in Röntgen, Sonografie, CT und MRT vorgestellt. Mithilfe der morphologischen Kriterien lassen sich oftmals einzelne Läsionstypen bzw. deren Malignitätsgrad nicht ausreichend abgrenzen. Daher spielen vor allem die funktionellen Informationen im PET und der MRT eine wichtige Rolle zur nicht invasiven Klassifikation. Zur Sicherung einer histologischen Diagnose steht mit den CT-gesteuerten Biopsiemöglichkeiten eine ambulant durchzuführende Option mit hoher diagnostischer Genauigkeit und geringen Komplikationen zur Verfügung.

show abstract

Application of the apparent diffusion coefficient in magnetic resonance imaging in an assessment of the early response to treatment in Hodgkin’s and non-Hodgkin’s lymphoma – pilot study

Cited by 3 publications

References 18 publications

Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma

Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma

Comparison between diffusion-weighted magnetic resonance and positron-emission tomography in the evaluation of treated lymphomas with mediastinal involvement

Bildgebung bei Mediastinaltumoren

Contact Info

Product

Resources

About